← The patent line

Triptorelin Pamoate

Sold as TRELSTAR, TRIPTODUR KIT · given by intramuscular

One to three years until it comes off patent
2.9 yr
Until anyone may copy it
Protection runs to 2029-06-30
14
Trials running now
290 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Azurity Pharmaceuticals Inc
Approval holder
the only company permitted to sell it today
2029-06
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

InfertilityProstate CancerBreast Cancer
03

Who is paying for the research

Ipsen
Company
6
ETOP IBCSG Partners Foundation
Research network
2
Fundación Santiago Dexeus Font
University or hospital
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07569315Phase 22026 · 190 people · not yet recruiting
Successive Doses of GnRH Agonist Versus Sing

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line